Harwin Peter Evan's Form 4 filing
Dianthus Therapeutics, Inc. (DNTH) · filed Sep 13, 2023
- Accession no.
- 0000950170-23-048022
- Filed
- Sep 13, 2023, 9:17 PM ET
- Trade date
- Sep 11-13, 2023
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market purchases total $271.7K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Harwin Peter EvanCIK 0001663607 | Director, 10% Owner |
| Fairmount Funds Management LLCCIK 0001802528 | Director, 10% Owner |
| Kiselak TomasCIK 0001830177 | Director, 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 12, 2023 | Common Stock | PPurchaseAcquired | +14,887 | $10.85 | +$161,523.95 | 1,834,466 | Indirect | |
| Sep 13, 2023 | Common Stock | PPurchaseAcquired | +9,367 | $11.76 | +$110,155.92 | 1,843,833 | Indirect |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 11, 2023 | Common Stock | AGrant or awardAcquired | +6,500 | $0.00 | $0 | 6,500 | Indirect | Duplicate filing |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.